At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 17,190 enrolled
Drug / intervention
Dapagliflozin 10 mg +1 moredrug
Likely dose
Dapagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin 10 mg and Placebo tablet for Diabetes Mellitus, Non-Insulin-Dependent and High Risk for Cardiovascular Event. Completed, enrolled 17,190 participants across 805 sites in 34 countries.
Detailed Summary
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States, Vietnam
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartApr 2013
Primary CompletionSep 2018
TodayJul 2026
First PostedNov 21, 2012
Enrollment StartApr 25, 2013
Primary CompletionSep 11, 2018
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 13.6 years ago
Interventions
Dapagliflozin 10 mgdrug
Oral dose (od)
Placebo tabletdrug
Oral dose (od)